Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 22, 2022
-
Jan 4, 2022- Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda®
-
Dec 1, 2021- Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
-
Nov 3, 2021
-
Oct 12, 2021-- Interim results from the Phase 1 study show a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose administered intravenously, or IV.
-
Oct 11, 2021- Event to be webcast live on Tuesday, October 12, 2021, at 5:30 a.m. PT -